Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood

G. Rivera, W. P. Bowman, A. T. Look, W. E. Evans, D. Kalwinsky, G. V. Dahl

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

In clinical trials conducted at St Jude Children's Research Hospital, etoposide has proved to be an effective agent for the treatment of advanced childhood leukemias. When combined with 5-azacytidine, it induced complete remissions in about one-half of patients with refractory ANLL. The same induction rate was achieved in patients with refractory ALL receiving etoposide with prednisone and vincristine. Results of continuing studies should help to identify the optimal schedules and dosages for this epipodophyllotoxin. The acceptance of new antileukemic drugs into clinical practice has slowed over the past decade. Etoposide is but one of several new agents that hold promise of moving leukemia therapy beyond its present barriers.

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalCancer Treatment Reviews
Volume9
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 1982

Fingerprint Dive into the research topics of 'Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood'. Together they form a unique fingerprint.

Cite this